Bigdeli Maryam, Javadi Dena, Hoebert Joelle, Laing Richard, Ranson Kent
Alliance for Health Policy and Systems Research, World Health Organization, 20, avenue Appia, 1211 Geneva, Switzerland.
Health Res Policy Syst. 2013 Oct 14;11:37. doi: 10.1186/1478-4505-11-37.
To identify priority policy issues in access to medicines (ATM) relevant for low- and middle-income countries, to identify research questions that would help address these policy issues, and to prioritize these research questions in a health policy and systems research (HPSR) agenda.
The study involved i) country- and regional-level priority-setting exercises performed in 17 countries across five regions, with a desk review of relevant grey and published literature combined with mapping and interviews of national and regional stakeholders; ii) interviews with global-level stakeholders; iii) a scoping of published literature; and iv) a consensus building exercise with global stakeholders which resulted in the formulation and ranking of HPSR questions in the field of ATM.
A list of 18 priority policy issues was established following analysis of country-, regional-, and global-level exercises. Eighteen research questions were formulated during the global stakeholders' meeting and ranked according to four ranking criteria (innovation, impact on health and health systems, equity, and lack of research). The top three research questions were: i) In risk protection schemes, which innovations and policies improve equitable access to and appropriate use of medicines, sustainability of the insurance system, and financial impact on the insured? ii) How can stakeholders use the information available in the system, e.g., price, availability, quality, utilization, registration, procurement, in a transparent way towards improving access and use of medicines? and iii) How do policies and other interventions into private markets, such as information, subsidies, price controls, donation, regulatory mechanisms, promotion practices, etc., impact on access to and appropriate use of medicines?
Our HPSR agenda adopts a health systems perspective and will guide relevant, innovative research, likely to bear an impact on health, health systems and equity.
确定与低收入和中等收入国家相关的药品获取(ATM)方面的优先政策问题,确定有助于解决这些政策问题的研究问题,并在卫生政策与系统研究(HPSR)议程中对这些研究问题进行优先排序。
该研究包括:i)在五个区域的17个国家进行国家和区域层面的优先事项确定活动,对相关灰色文献和已发表文献进行案头审查,并结合对国家和区域利益相关者的映射和访谈;ii)对全球层面利益相关者的访谈;iii)已发表文献的范围界定;iv)与全球利益相关者进行共识构建活动,从而形成并排列ATM领域的HPSR问题。
在分析国家、区域和全球层面的活动后,确定了18个优先政策问题清单。在全球利益相关者会议期间制定了18个研究问题,并根据四个排序标准(创新性、对健康和卫生系统的影响、公平性以及研究不足)进行了排序。排名前三的研究问题是:i)在风险保护计划中,哪些创新和政策可改善药品的公平获取和合理使用、保险系统的可持续性以及对被保险人的财务影响?ii)利益相关者如何以透明的方式利用系统中可用的信息,例如价格、可及性、质量、使用情况、注册、采购等,以改善药品的获取和使用?iii)对私营市场的政策和其他干预措施,如信息、补贴、价格管制、捐赠、监管机制、推广做法等,如何影响药品的获取和合理使用?
我们的HPSR议程采用卫生系统视角,将指导相关的创新性研究,可能对健康、卫生系统和公平性产生影响。